Using DNA to develop encoded libraries of pharmacological leads has enabled medical research community to assemble and maintain large collections of compounds in singular reaction tubes, capturing the attention of small and big pharma players
The approval of KYMRIAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity.
Rise in prevalence of chronic diseases and the corresponding need to medicate frequently, have led to an increase in demand for safe, self-administrable dosing options. Autoinjectors are considered among the leading product classes in this category
In order to reduce risk of device recalls and expedite time to market, medical device developers rely on contract service providers for regulatory submissions and navigating various challenging aspects of the product review and approval process
With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone